Jan 10, 2022 / 01:15PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Welcome to the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it's my great pleasure to host Vas Narasimhan, the CEO of Novartis, in this session. Before I hand over to Vas for his presentation, I just remind people to post their questions on the section of the website, and then I'll ask them for you once Vas has finished his presentation. With that, welcome, Vas, over to you.
Vasant Narasimhan - Novartis AG - CEO
Thank you, Richard, and it's great to be here with everyone today, and thank you for joining my session. If we could get the slides up. Terrific.
So what I'd like to go over with you today is an update on the Novartis strategy, our growth story, our efforts to reimagine medicine to improve human health all around the world. Now if you go to the first slide on the next slide, when we think about the story we present to investors, we think there's 5 critical elements that are worthwhile for investors to consider as they
Novartis AG at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers